Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Stock Information for Ventyx Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ventyx Biosciences Inc.

Ventyx Provides Clinical and Corporate Updates
Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London
Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.